Brief: Acasti Announces Wuxi Clinical As Cro To Conduct Strive-On Pivotal Phase 3 Safety Trial For Gtx-104 In Asah Patients

Grace Therapeutics

10/07/2023 14:09

Acasti Pharma Inc  ACST.O :
    * ACASTI ANNOUNCES WUXI CLINICAL AS CRO TO CONDUCT STRIVE-ON
PIVOTAL PHASE 3 SAFETY TRIAL FOR GTX-104 IN ASAH PATIENTS
    * ACASTI PHARMA INC - ANTICIPATING DOSING FIRST PATIENT IN
FOURTH
CALENDAR QUARTER OF 2023 AND A POTENTIAL NDA SUBMISSION IN FIRST
HALF OF CALENDAR 2025

Source text for Eikon:  ID:nPn6YpvRYa 
Further company coverage:  ACST.O